Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
Metastatic Colorectal Cancer
DRUG: Bevacizumab
time to progression, 6 months
overall survival, safety, response, 1 year
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.